Melanoma

Jose Lutzky, MD, discusses clinical trials investigating novel therapies for melanoma.

Jose Lutzky, MD, discusses the innovative tumor-inflitrating lymphocyte therapy for the treatment of relapsed or refractory melanoma.

Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.

A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Lifileucel's FDA approval marks a breakthrough in melanoma treatment, offering hope with promising antitumor activity. While its potential extends to various solid tumors, challenges persist.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.

It is a promising time for cellular therapy, and combinations with gene modification or other systemic or local therapies bode well for solid tumor development of this TIL therapy platform.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.

The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed tolerability factors that could influence the choice of frontline immunotherapy regimen for a patient with metastatic melanoma.

Dr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.

Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.

Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.

An expert perspective on how to best treat a patient diagnosed with stage IV BRAF-mutated melanoma.

Dr Atkins shares his approach to first-line treatment and reviews data regarding treatment sequencing from the DREAMseq Trial.

An overview of treatments for metastatic melanoma, including data updates regarding combination options.

Michael B Atkins, MD, shares insights on the prognosis of patient’s diagnosed with advanced melanoma and discusses the value of BRAF mutation testing.

Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.